4.4 Benzodiazepines, Z-drugs, Barbiturates, and Major Anticonvulsants

Sedative-hypnotics and anticonvulsants encompass chemically diverse classes utilized for insomnia, anxiety, epilepsy, and neuropathic disorders. Their toxicological profiles range from relatively benign central nervous system depression with intact cardiopulmonary stability to catastrophic multi-organ failure, hyperammonemic encephalopathy, and fatal status epilepticus. Poison information specialists must master the unique toxicokinetics, elimination pathways, and specific antidote contraindications governing these critical agents.

---

Benzodiazepines and Non-Benzodiazepine Z-Drugs

1. Benzodiazepines: Pharmacology and Overdose Phenotype

Benzodiazepines—such as diazepam, lorazepam, alprazolam, clonazepam, and midazolam—bind to a specific allosteric regulatory site located at the interface of the alpha and gamma-2 subunits of the pentameric GABA-A receptor chloride channel complex:

• Electrophysiological Mechanism: Binding enhances the receptor's affinity for endogenous GABA, increasing the frequency of chloride channel opening events. Inward chloride flux hyperpolarizes the postsynaptic neuronal membrane, suppressing action potential generation.
• Clinical Presentation: The hallmark of pure oral benzodiazepine overdose is central nervous system depression (somnolence, ataxia, dysarthria, anterograde amnesia) in the presence of normal or near-normal vital signs ("coma with normal vitals").
• Co-Ingestion Pearl: Significant respiratory depression, severe hypotension, or deep unarousable coma in a presumed benzodiazepine ingestion strongly indicates the presence of a co-ingestant—most commonly ethanol, opioids, barbiturates, or GHB—or an underlying pulmonary pathology.

2. Flumazenil: Indications and Lethal Contraindications

Flumazenil is an imidazobenzodiazepine derivative that functions as a competitive antagonist at the benzodiazepine recognition site on the GABA-A receptor. It rapidly reverses sedation and psychomotor impairment within 1 to 3 minutes of intravenous administration.

Despite its pharmacological efficacy, routine flumazenil administration is strictly contraindicated in the management of undifferentiated sedative overdose due to substantial clinical risks:

• Precipitation of Fatal Withdrawal Status Epilepticus: In individuals with chronic benzodiazepine use or physiological dependence, flumazenil abruptly removes GABAergic tone, triggering severe acute withdrawal, autonomic instability, and intractable status epilepticus that is resistant to benzodiazepine re-administration.
• Unmasking of Proconvulsant Co-Ingestants: In polypharmacy ingestions involving proconvulsant agents—most notably Tricyclic Antidepressants (TCAs), bupropion, or theophylline—benzodiazepines provide a protective anticonvulsant brake. Administering flumazenil removes this protective inhibition, unleashing refractory seizures, severe metabolic acidosis, and fatal ventricular arrhythmias.
• True Indications for Flumazenil: Flumazenil is safely reserved for two specific scenarios: (1) reversal of procedural conscious sedation in an opioid/sedative-naive patient who received a known, isolated benzodiazepine, and (2) isolated accidental pediatric ingestions with airway compromise where the child is known to be benzodiazepine-naive.
• Operational Poison Center Rule: Supportive airway management (positioning, suctioning, supplemental oxygen, or endotracheal intubation) is vastly safer than flumazenil administration for comatose patients with undifferentiated overdose.

3. Non-Benzodiazepine Z-Drugs

Z-drugs—comprising zolpidem, zaleplon, and eszopiclone—are non-benzodiazepine hypnotics that bind selectively to the alpha-1 subunit of the GABA-A receptor, the subunit primarily mediating sedation and hypnotic actions:

• Clinical Manifestations: Rapid onset of somnolence, ataxia, dizziness, visual hallucinations, and complex sleep behaviors (sleepwalking, nocturnal binge eating, sleep-driving). Overdoses are generally mild in isolation, though massive ingestions can produce respiratory depression and coma.
• Reversal: Flumazenil reverses Z-drug sedation, but the same clinical contraindications regarding tolerance and proconvulsant co-ingestants apply.

---

Barbiturates: Toxicity and Enhanced Elimination

Mechanism of Action and Clinical Toxicity

Barbiturates—including ultra-short-acting (thiopental), short/intermediate-acting (pentobarbital, secobarbital, butalbital), and long-acting (phenobarbital) compounds—bind to the beta subunit of the GABA-A receptor:

• Dual Molecular Action: Unlike benzodiazepines, barbiturates increase the duration of chloride channel opening. Furthermore, at elevated concentrations, barbiturates act as direct GABA mimetics (opening chloride channels even in the complete absence of GABA) and directly inhibit excitatory AMPA and kainate glutamate receptors. This dual mechanism produces profound, uncoupled central nervous system and cardiopulmonary depression.
• Overdose Presentation: Deep coma, severe respiratory depression, hypothermia, marked bradycardia, hypotension, loss of all brainstem reflexes (a clinical state mimicking brain death), and cutaneous bullae ("barbiturate blisters") over dependent pressure points and bony prominences.

Enhanced Elimination for Phenobarbital

Phenobarbital is a weak acid with a pKa of 7.24, low plasma protein binding (~50%), and significant renal clearance. In severe phenobarbital overdose, two enhanced elimination modalities are highly effective:

1. Urinary Alkalinization (Ion Trapping):
   • Mechanism: Administering IV sodium bicarbonate to raise systemic blood pH and maintain a urine pH between 7.5 and 8.0 shifts phenobarbital in the renal tubular lumen into its charged, ionized conjugate base form. The charged molecule cannot cross the lipophilic tubular membrane, preventing reabsorption and increasing renal clearance 5- to 10-fold.
   • Infusion Protocol: Mix 150 mEq NaHCO3 in 1 L D5W, infuse at 150 to 250 mL/hr, and monitor urine pH hourly alongside serum potassium.
2. Multiple-Dose Activated Charcoal (MDAC):
   • Mechanism: Administering repeated doses of activated charcoal (0.5 g/kg every 2 to 4 hours) performs "gastrointestinal dialysis." It creates a concentration gradient across the mesenteric capillary bed, drawing phenobarbital from systemic circulation into the intestinal lumen, while simultaneously interrupting enterohepatic circulation.
3. Extracorporeal Elimination (Hemodialysis): EXTRIP recommends ECTR in severe long-acting barbiturate poisoning when prolonged coma is present or expected, when shock persists after fluid resuscitation, or when toxicity persists despite MDAC; it suggests ECTR when concentrations keep rising despite MDAC or when mechanical ventilation is required. The decision is clinical, not a single level cutoff.

Critical Distinction — Short-Acting Barbiturates: Urinary alkalinization and MDAC are ineffective for short-acting barbiturates (pentobarbital, secobarbital, butalbital) because these agents have high lipid solubility and undergo near-complete hepatic metabolism with negligible renal clearance.

---

Valproic Acid (VPA / Sodium Valproate)

Mechanisms of Toxicity

Valproic acid enhances central GABAergic transmission, blocks T-type calcium channels, and alters mitochondrial fatty acid metabolism. Acute overdose produces dose-dependent lethargy, somnolence, coma, respiratory depression, anion gap metabolic acidosis, hyperosmolality, and hypernatremia (resulting from the sodium valproate formulation). Delayed complications (24 to 72 hours) include acute pancreatitis, bone marrow suppression (thrombocytopenia), and cerebral edema.

Valproate-Induced Hyperammonemic Encephalopathy (VHE)

VHE is a severe, life-threatening metabolic complication that can occur during chronic therapy or following acute overdose:

• Biochemical Pathophysiology: Valproic acid is metabolized to valproyl-CoA, which directly inhibits carbamoyl phosphate synthetase I (CPS I)—the initial, rate-limiting enzyme of the hepatic urea cycle. Additionally, valproate depletes systemic stores of L-carnitine through the formation and renal excretion of valproylcarnitine. Carnitine depletion blocks mitochondrial beta-oxidation of fatty acids, depleting acetyl-CoA (the essential allosteric activator of CPS I). With CPS I inhibited, ammonia cannot enter the urea cycle, leading to acute accumulation of neurotoxic ammonia.
• Clinical Presentation: Deepening lethargy, asterixis, cognitive blunting, vomiting, seizures, and cerebral edema.
• High-Yield Diagnostic Hallmark: Serum ammonia is markedly elevated (often >150 to 300 mcmol/L) despite completely normal serum transaminases (AST/ALT) and total bilirubin; VHE is a functional metabolic defect, not acute hepatocellular necrosis.

Antidote Therapy: Intravenous L-Carnitine (Levocarnitine)

L-Carnitine replenishes free carnitine pools, restores mitochondrial beta-oxidation, boosts intramitochondrial acetyl-CoA production, and reactivates CPS I, rapidly clearing systemic ammonia:

• Dosing Regimen: Administer an IV loading dose of 100 mg/kg (maximum single dose 6.0 grams) infused over 30 minutes, followed by maintenance infusions of 15 mg/kg IV every 4 hours until serum ammonia normalizes and encephalopathy resolves.

Extracorporeal Elimination (Hemodialysis)

At therapeutic concentrations (50 to 100 mcg/mL), valproic acid is 90% to 95% bound to plasma albumin. However, at toxic concentrations (>150 to 300 mcg/mL), albumin binding sites become completely saturated, causing the free (unbound), dialyzable fraction of the drug to rise precipitously. The EXTRIP workgroup recommends extracorporeal treatment (intermittent hemodialysis preferred) when the VPA concentration exceeds 1,300 mg/L, or when shock or cerebral edema is present. It suggests ECTR when the concentration exceeds 900 mg/L, or with coma or respiratory depression requiring mechanical ventilation, acute hyperammonemia, or pH below 7.10.

---

Carbamazepine and Phenytoin

1. Carbamazepine

Carbamazepine is a dibenzazepine derivative structurally related to tricyclic antidepressants. It blocks voltage-gated fast sodium channels and has anticholinergic properties:

• Toxicokinetics: Highly lipophilic with slow, erratic gastrointestinal absorption. In overdose, peak serum concentrations are frequently delayed by 24 to 72 hours due to tablet coalescence and pharmacobezoar formation. Carbamazepine is metabolized via CYP3A4 to an active, neurotoxic metabolite: carbamazepine-10,11-epoxide.
• Clinical Manifestations: Characterized by fluctuating or "cyclical" coma (alternating between deep unarousable coma and combative agitation as tablets dissolve erratically), nystagmus, ataxia, mydriasis, urinary retention, seizures, and cardiac conduction delays (QRS widening, AV blocks).
• Elimination Strategies: Multiple-dose activated charcoal (MDAC) accelerates clearance by interrupting enterohepatic recycling. EXTRIP recommends ECTR (intermittent hemodialysis preferred) for multiple seizures refractory to treatment or life-threatening dysrhythmias, and suggests it for prolonged coma or respiratory depression requiring ventilation, or for significant toxicity that persists (especially with rising levels) despite MDAC. EXTRIP does not use a single concentration cutoff.

2. Phenytoin and Fosphenytoin

Phenytoin suppresses seizure propagation by stabilizing the inactive state of voltage-gated neuronal sodium channels.

Michaelis-Menten (Zero-Order) Saturation Kinetics

Within and just above the therapeutic window (10 to 20 mcg/mL), hepatic biotransformation enzymes (CYP2C9 and CYP2C19) become fully saturated. Clearance shifts from first-order (fixed percentage per unit time) to zero-order elimination (fixed absolute amount per unit time). Small incremental dose increases or overdoses provoke massive, disproportionate surges in serum concentration, extending the drug's elimination half-life from 24 hours to greater than 100 to 200 hours.

Clinical Manifestations by Serum Concentration

• 10 to 20 mcg/mL: Therapeutic range.
• 20 to 30 mcg/mL: Far-lateral gaze horizontal nystagmus.
• 30 to 40 mcg/mL: Prominent cerebellar ataxia, slurred speech, tremors, nausea, vomiting.
• 40 to 50 mcg/mL: Severe lethargy, confusion, choreoathetosis, marked encephalopathy.
• > 50 mcg/mL: Stupor, coma, and paradoxical seizures (rare, occurring at extreme concentrations >60–80 mcg/mL).

High-Yield Distinction: Oral vs. Intravenous Phenytoin Toxicity

• Oral Phenytoin Overdose: Manifests as purely neuro-vestibular toxicity (nystagmus, ataxia, dysarthria, lethargy). Oral overdose does not cause cardiac conduction blocks, dysrhythmias, or hypotension. Oral phenytoin is safe from a cardiovascular standpoint; intensive cardiac telemetry is unnecessary in isolated oral ingestions.
• Intravenous Phenytoin Toxicity: Parenteral phenytoin is formulated with 40% Propylene Glycol as a solubilizing diluent and sodium hydroxide (pH 12). Rapid IV infusion precipitates severe myocardial depression, profound bradycardia, hypotension, heart block, and asystole, mediated directly by the propylene glycol solvent and rapid cardiac sodium channel inhibition. Propylene glycol toxicity also causes hyperosmolality, lactic acidosis, and acute tubular necrosis. The maximum safe IV infusion rate is 50 mg/min in adults (1 mg/kg/min in pediatrics/elderly). Extravasation causes severe chemical endarteritis, tissue necrosis, and ischemia known as "Purple Glove Syndrome."
• Fosphenytoin: A water-soluble prodrug that contains no propylene glycol and is formulated at a much less alkaline pH (8.6–9.0). It eliminates purple glove syndrome and significantly reduces solvent-mediated hypotension. It can be administered at infusion rates up to 150 mg phenytoin equivalents (PE)/min, though rapid infusion can still cause transient paresthesias and pruritus.

Other Anticonvulsants and Sedative-Hypnotics on the CSPI Topic List

The official CSPI topic list names several agents beyond the "big three" anticonvulsants. Their overdose profiles are distinctive enough to be tested directly.

How to Use These in Triage

1. Match the toxidrome to the agent. Sedation plus a wide QRS points to sodium channel blockers (lamotrigine, carbamazepine, TCAs). Sedation plus a normal-gap acidosis points to topiramate.
2. Ask about kidney function. Gabapentin and pregabalin are renally cleared; accumulation causes confusion and sedation in older adults with chronic kidney disease.
3. Treat seizures with benzodiazepines first. Phenytoin does not help drug-induced seizures and is avoided when sodium channel blockade is present.
4. Remember chloral hydrate's heart. Its metabolite trichloroethanol sensitizes the myocardium, so catecholamines can trigger dysrhythmias; beta-blockers are the treatment of choice.